FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileDisc Medicine, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
IRON
Disc Medicine, Inc. Stock AnalysisComprehensive stock analysis for Disc Medicine, Inc. (IRON) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisIRON
IRON
Disc Medicine, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
IRON
  1. Home
  2. Stocks
  3. Disc Medicine, Inc.
IR

Disc Medicine, Inc.

🇺🇸IRON•NASDAQ
IR

Disc Medicine, Inc.

🇺🇸IRON•NASDAQ
Market cap
$2.88B

Your view on IRON

Mkt Cap
$2.88B
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Disc Medicine, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
John D. Quisel
Headquarters
321 Arsenal Street, Watertown, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
John D. Quisel
Headquarters
321 Arsenal Street, Watertown, MA, US
Description

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.

It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Disc Medicine, Inc.. Starting points for Disc Medicine, Inc.: EPS -$6.25, beta 2.01 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Disc Medicine, Inc.. Trailing twelve-month EPS for Disc Medicine, Inc. stands at -$6.25. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
Analysts' target$120.50average of 10 firms, last 12 months
Current price—

Buy

Targets, low to high

$120.50

Low $88.00

Middle $118.50

High $170.00

Analyst ratings

8 firms, last 12 months
  • Strong Buy0
  • Buy8
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$1.47−$1.51−$5.90−$5.95
Lowest estimate−$1.62−$1.54−$6.07−$7.17
Highest estimate−$1.39−$1.47−$5.80−$5.17
Number of analysts7599
A year ago−$1.62−$1.65−$6.01—
Growth vs a year ago+9.3%+8.4%+1.8%—

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$3.70M$0.00$3.16M$43.54M
Lowest estimate$3.70M$0.00$1.61M$8.61M
Highest estimate$3.70M$0.00$6.54M$70.95M
Number of analysts90710
A year ago$0.00$0.00$0.00—
Growth vs a year ago————
Recent rating and target changes (15)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Disc Medicine, Inc.. Disc Medicine, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold IRON17 companies · 8 funds
Compare IRON with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
AGIOAgios Pharmaceuticals, Inc.HealthcareBiotechnology$1.7B
COAGHemab Therapeutics Holdings, Inc. Common StockHealthcareBiotechnology$1.8B
DMRADamora Therapeutics, Inc.HealthcareBiotechnology$1.4B
GERNGeron CorporationHealthcareBiotechnology$560.9M
PTGXProtagonist Therapeutics, Inc.HealthcareBiotechnology$7.9B
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
RLFTFRelief Therapeutics Holding AGHealthcareOTC$11.9M
RLFTYMindMaze Therapeutics Holding S.A. Sponsored ADRHealthcareOTC$12.0M
RLMDRelmada Therapeutics, Inc.HealthcareNASDAQ$279.5M
RLYBRallybio CorporationHealthcareNASDAQ$83.3M
RMTGRegenerative Medical Technology Group Inc.HealthcareOTC$488,770
RNAAvidity Biosciences, Inc.HealthcareNASDAQ$149.3M
RNACCartesian Therapeutics, Inc.HealthcareNASDAQ$187.3M
RNAZTransCode Therapeutics, Inc.HealthcareNASDAQ$1.2M
RNTXRein Therapeutics Inc.HealthcareNASDAQ$29.1M
RNUGFReNeuron Group plcHealthcareOTC$62,891
RNXTRenovoRx, Inc.HealthcareNASDAQ$45.5M
ROIVRoivant Sciences Ltd.HealthcareNASDAQ$28.0B
ETFs holding Disc Medicine, Inc.
TickerFundFund assets% of the fund
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
IWMiShares Russell 2000 ETF$76.6B in assets0.09%
XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.58%
VXFVanguard Extended Market ETF$30.2B in assets0.04%
SBIOALPS Medical Breakthroughs ETF$187M in assets2.07%
VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.17%
TMSLT. Rowe Price Small-Mid Cap ETF$3.2B in assets0.17%
IBBiShares Biotechnology ETF$11.1B in assets0.16%

Largest holders first, then the funds most concentrated in IRON.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Disc Medicine, Inc., and how their positions are changing. At a $2.88B market value, institutional positions materially move Disc Medicine, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Disc Medicine, Inc. executives and directors. Shares of Disc Medicine, Inc. have traded between $30.82 and $95.95 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Disc Medicine, Inc.. Coverage tracks Disc Medicine, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Disc Medicine, Inc.

IRON AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1